article thumbnail

Sandoz delivers 6% sales growth with Humira biosimilar leading the charge

Fierce Pharma

With Hyrimoz leading the way, sales of the company’s biosimilars reached $623 million in the first three months of this year. . | After spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab).

Leads 268
article thumbnail

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts

Fierce Pharma

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

Leads 156
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis leads race to acquire Monjuvi maker MorphoSys: Reuters

Fierce Pharma

After Novartis reportedly backed out of late-stage talks to acquire Cytoki | The company has a leading bid for the cancer drug maker over Incyte, Reuters reports, citing two people familiar with the matter.

Leads 235
article thumbnail

In gene therapy race, bluebird leads Vertex in activating treatment centers but trails in patient starts

Fierce Pharma

While Vertex leads in patient starts, bluebird has activated more treatment centers. It’s not an easy question to answer.

Leads 238
article thumbnail

JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030

Fierce Pharma

In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | Morgan Healthcare Conference.

Leads 270
article thumbnail

M&A Monday: AstraZeneca Leads Way as Three Pharmas Splash Out $3.5B in Deals

MedCity News

billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. AstraZeneca has committed $1.3 In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.

Leads 108
article thumbnail

Fierce Pharma Asia—Astellas' brief IRA fight; Otsuka's psychedelic buy; Takeda's court loss

Fierce Pharma

Three Japanese pharma companies lead our news stories from Asia this week. Astellas has abandoned its challenge against the Inflation Reduction Act. Astellas has abandoned its challenge against the Inflation Reduction Act. Otsuka bought a Canadian psychedelic biotech.

Pharma 203